The Role of Neutrophils as a Driver in Hepatic Ischemia-Reperfusion Injury and Cancer Growth.
cancer liver
ischemia reperfusion (I/R) injury
liver transplantation
neutrophil
neutrophil extracelluar traps
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
03
2022
accepted:
02
06
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
The innate immune system plays an essential role in the response to sterile inflammation and its association with liver ischemia and reperfusion injury (IRI). Liver IRI often manifests during times of surgical stress such as cancer surgery or liver transplantation. Following the initiation of liver IRI, stressed hepatocytes release damage-associated molecular patterns (DAMPs) which promote the infiltration of innate immune cells which then initiate an inflammatory cascade and cytokine storm. Upon reperfusion, neutrophils are among the first cells that infiltrate the liver. Within the liver, neutrophils play an important role in fueling tissue damage and tumor progression by promoting the metastatic cascade through the formation of Neutrophil Extracellular Traps (NETs). NETs are composed of web-like DNA structures containing proteins that are released in response to inflammatory stimuli in the environment. Additionally, NETs can aid in mediating liver IRI, promoting tumor progression, and most recently, in mediating early graft rejection in liver transplantation. In this review we aim to summarize the current knowledge of innate immune cells, with a focus on neutrophils, and their role in mediating IRI in mouse and human diseases, including cancer and transplantation. Moreover, we will investigate the interaction of Neutrophils with varying subtypes of other cells. Furthermore, we will discuss the role and different treatment modalities in targeting Neutrophils and NETs to prevent IRI.
Identifiants
pubmed: 35844608
doi: 10.3389/fimmu.2022.887565
pmc: PMC9284204
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
887565Informations de copyright
Copyright © 2022 Kaltenmeier, Yazdani, Handu, Popp, Geller and Tohme.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Hepatol. 2014 Feb;60(2):298-305
pubmed: 24060854
Exp Ther Med. 2021 Mar;21(3):223
pubmed: 33603832
Exp Ther Med. 2018 Oct;16(4):3399-3404
pubmed: 30233687
Curr Transplant Rep. 2019;6(1):78-89
pubmed: 31602356
Nature. 2020 Jul;583(7814):133-138
pubmed: 32528174
Lupus. 1999;8(1):68-76
pubmed: 10025601
Am J Surg. 2015 May;209(5):870-4
pubmed: 25805455
Hepatology. 2002 Sep;36(3):562-72
pubmed: 12198648
Transl Res. 2010 Jun;155(6):294-304
pubmed: 20478544
Am J Transplant. 2011 Aug;11(8):1563-9
pubmed: 21668640
Hepatology. 2015 Aug;62(2):600-14
pubmed: 25855125
Am J Physiol. 1991 Mar;260(3 Pt 1):G355-62
pubmed: 2003603
Cancer Res. 2016 Mar 15;76(6):1367-80
pubmed: 26759232
PLoS One. 2012;7(4):e35379
pubmed: 22514737
Cancers (Basel). 2021 Dec 06;13(23):
pubmed: 34885240
Liver Int. 2019 May;39(5):788-801
pubmed: 30843314
Front Immunol. 2021 Oct 19;12:716250
pubmed: 34737738
J Innate Immun. 2013;5(4):315-23
pubmed: 23486162
J Exp Clin Cancer Res. 2019 Dec 12;38(1):489
pubmed: 31831037
Nanotechnology. 2021 Apr 06;32(26):
pubmed: 33472187
Hepatology. 2013 Jan;57(1):339-50
pubmed: 22961591
J Biomed Res. 2019 Jul 28;33(4):221-234
pubmed: 32383437
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31672934
Front Immunol. 2020 May 22;11:987
pubmed: 32528475
J Hepatol. 2017 Sep 21;:
pubmed: 28943296
Curr Opin Crit Care. 2019 Dec;25(6):717-722
pubmed: 31689246
Clin Transplant. 2017 Feb;31(2):
pubmed: 28004856
J Immunol. 2011 Jul 1;187(1):490-500
pubmed: 21606249
Immune Netw. 2018 Aug 13;18(4):e27
pubmed: 30181915
J Immunol. 2019 Jan 1;202(1):268-277
pubmed: 30504418
Life Sci. 2003 May 2;72(24):2707-18
pubmed: 12679188
Cancer Res. 2019 Nov 1;79(21):5626-5639
pubmed: 31519688
Nat Rev Immunol. 2015 Oct;15(10):597
pubmed: 26388330
J Leukoc Biol. 2021 Oct;110(4):797-808
pubmed: 33378572
Blood. 2017 Mar 9;129(10):1343-1356
pubmed: 28053192
Hepatology. 2021 Jun;73(6):2494-2509
pubmed: 32924145
Cell Death Discov. 2020 Apr 22;6:26
pubmed: 32351713
Cell Immunol. 2018 Apr;326:52-59
pubmed: 28860007
Biomolecules. 2019 Aug 14;9(8):
pubmed: 31416173
Nat Commun. 2019 Mar 21;10(1):1322
pubmed: 30899022
Hepatology. 2017 Jul;66(1):182-197
pubmed: 28370295
Cell Death Dis. 2018 Feb 23;9(3):323
pubmed: 29476069
J Cell Death. 2014 May 08;7:15-23
pubmed: 25278783
Hepatology. 2018 Oct;68(4):1347-1360
pubmed: 29631332
Immunology. 2019 Jan;156(1):23-32
pubmed: 30259972
Front Immunol. 2021 Nov 24;12:785222
pubmed: 34899751
Cancer Immunol Res. 2021 Jul;9(7):811-824
pubmed: 33906865
Transplantation. 2022 Feb 1;106(2):e126-e140
pubmed: 34534191
J Clin Invest. 2020 May 1;130(5):2689-2704
pubmed: 32027621
Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1116-23
pubmed: 15246960
J Hepatol. 2021 Sep;75(3):503-505
pubmed: 34274367
Toxicol Sci. 2010 Jun;115(2):307-21
pubmed: 20071422
J Immunol. 2010 Dec 1;185(11):7057-66
pubmed: 21037096
Cancer Res. 2017 Apr 1;77(7):1548-1552
pubmed: 28330928
Cell Death Differ. 2017 Apr;24(4):683-693
pubmed: 28157209
J Immunol. 2012 Sep 15;189(6):2689-95
pubmed: 22956760
Exp Cell Res. 2017 Feb 1;351(1):91-99
pubmed: 28077302
Aliment Pharmacol Ther. 2015 Jan;41(2):189-98
pubmed: 25382796
Front Pharmacol. 2021 Apr 15;12:655557
pubmed: 33935770
Cell Biosci. 2021 Jan 6;11(1):3
pubmed: 33407858
Lab Invest. 2018 Jan;98(1):51-62
pubmed: 28920945
Int J Mol Sci. 2019 May 02;20(9):
pubmed: 31052493
Int Rev Cell Mol Biol. 2012;298:229-317
pubmed: 22878108